Tumor-initiating CD49f cells are a hallmark of chemoresistant triple negative breast cancer

Tumor-initiating CD49f cells are a hallmark of chemoresistant triple negative breast cancer

Taxanes are mainstay treatment of triple negative breast cancer (TNBC) patients but resistance often develops. Using TNBC patient-derived orthoxenografts (PDX) we have recently discovered that a CD49f+ chemoresistant population with tumor-initiating ability is present in sensitive tumors and expands...

Full description

Bibliographic Details
Main Authors:	Jorge Gomez-Miragaya, Eva González-Suárez
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2017-07-01
Series:	Molecular & Cellular Oncology
Subjects:	cd49f tumor-initiating cells chemoresistance docetaxel pdx (patient-derived orthoxenografts) triple negative breast cancer (tnbc)
Online Access:	http://dx.doi.org/10.1080/23723556.2017.1338208

Similar Items

Aptamer Targets Triple-Negative Breast Cancer through Specific Binding to Surface CD49c
by: Quanyuan Wan, et al.
Published: (2022-03-01)

Functional inhibition of the RNA‐binding protein HuR sensitizes triple‐negative breast cancer to chemotherapy
by: Lanjing Wei, et al.
Published: (2023-10-01)

DSTYK Enhances Chemoresistance in Triple-Negative Breast Cancer Cells
by: Stella C. Ogbu, et al.
Published: (2021-12-01)

Therapeutic Effects of Dietary Soybean Genistein on Triple-Negative Breast Cancer via Regulation of Epigenetic Mechanisms
by: Manvi Sharma, et al.
Published: (2021-11-01)

The Oxygen-Generating Calcium Peroxide-Modified Magnetic Nanoparticles Attenuate Hypoxia-Induced Chemoresistance in Triple-Negative Breast Cancer
by: Fong-Yu Cheng, et al.
Published: (2021-02-01)

Association of CD206 Protein Expression with Immune Infiltration and Prognosis in Patients with Triple-Negative Breast Cancer
by: Angélique Bobrie, et al.
Published: (2022-10-01)

Tissue Inhibitor of Metalloproteinases-1 Overexpression Mediates Chemoresistance in Triple-Negative Breast Cancer Cells
by: Lisa Agnello, et al.
Published: (2023-07-01)

A review of biological targets and therapeutic approaches in the management of triple-negative breast cancer
by: Hitesh Kumar, et al.
Published: (2023-12-01)

Characterizing the Inflammatory Profile of Neutrophil-Rich Triple-Negative Breast Cancer
by: Fatma Al Qutami, et al.
Published: (2024-02-01)

RUNX2 facilitates aggressiveness and chemoresistance of triple negative breast cancer cells via activating MMP1
by: Wentao Si, et al.
Published: (2022-11-01)

Therapeutic Strategies for Metastatic Triple-Negative Breast Cancers: From Negative to Positive
by: Dey Nandini, et al.
Published: (2021-05-01)

In Vitro Evaluation of NLS-DTX Activity in Triple-Negative Breast Cancer
by: Karen L. R. Paiva, et al.
Published: (2022-08-01)

Prognostic Impact of CD38- and IgκC-Positive Tumor-Infiltrating Plasma Cells in Triple-Negative Breast Cancer
by: Anne-Sophie Heimes, et al.
Published: (2023-10-01)

Altered Adipokine Expression in Tumor Microenvironment Promotes Development of Triple Negative Breast Cancer
by: Efthymia Papakonstantinou, et al.
Published: (2022-08-01)

Mechanistic Involvement of Long Non-Coding RNAs in Oncotherapeutics Resistance in Triple-Negative Breast Cancer
by: Samarth Kansara, et al.
Published: (2020-06-01)

Doxorubicin-polyglycerol-nanodiamond conjugate is a cytostatic agent that evades chemoresistance and reverses cancer-induced immunosuppression in triple-negative breast cancer
by: Shen-Jun Yuan, et al.
Published: (2019-10-01)

Ferroptosis induction via targeting metabolic alterations in triple-negative breast cancer
by: Yaru Wang, et al.
Published: (2023-12-01)

New Achievements for the Treatment of Triple-Negative Breast Cancer
by: Alessia Catalano, et al.
Published: (2022-05-01)

The Role of Breast Cancer Stem Cells in Chemoresistance and Metastasis in Triple-Negative Breast Cancer
by: Lin He, et al.
Published: (2021-12-01)

Emergence of Nanotechnology as a Powerful Cavalry against Triple-Negative Breast Cancer (TNBC)
by: Aiswarya Chaudhuri, et al.
Published: (2022-04-01)

Precision Medicine and Triple-Negative Breast Cancer: Current Landscape and Future Directions
by: Fokhrul Hossain, et al.
Published: (2021-07-01)

Cyclodextrin Diethyldithiocarbamate Copper II Inclusion Complexes: A Promising Chemotherapeutic Delivery System against Chemoresistant Triple Negative Breast Cancer Cell Lines
by: Ammar Said Suliman, et al.
Published: (2021-01-01)

USP7 Induces Chemoresistance in Triple-Negative Breast Cancer via Deubiquitination and Stabilization of ABCB1
by: Yueh-Te Lin, et al.
Published: (2022-10-01)

M6A demethylase ALKBH5 regulates FOXO1 mRNA stability and chemoresistance in triple-negative breast cancer
by: Xi Liu, et al.
Published: (2024-02-01)

Necroptosis Induced by Delta-Tocotrienol Overcomes Docetaxel Chemoresistance in Prostate Cancer Cells
by: Marina Montagnani Marelli, et al.
Published: (2023-03-01)

RUNX1 Is Regulated by Androgen Receptor to Promote Cancer Stem Markers and Chemotherapy Resistance in Triple Negative Breast Cancer
by: Natalia B. Fernández, et al.
Published: (2023-01-01)

Signaling Pathways and Natural Compounds in Triple-Negative Breast Cancer Cell Line
by: Citra Dewi, et al.
Published: (2022-06-01)

Efficacy and Safety of Capecitabine for Triple-Negative Breast Cancer: A Meta-Analysis
by: Xueqiong Xun, et al.
Published: (2022-07-01)

Antisense Oligonucleotide-Based Therapeutic against Menin for Triple-Negative Breast Cancer Treatment
by: Dang Tan Nguyen, et al.
Published: (2021-07-01)

Epidemiology, Pattern of Recurrence and Survival in Triple-negative Breast Cancer
by: Dharmendra Singh, et al.
Published: (2020-06-01)

New Biomarkers and Treatment Advances in Triple-Negative Breast Cancer
by: Brahim El Hejjioui, et al.
Published: (2023-06-01)

Editorial: Targeting triple negative breast cancer by natural compounds
by: Shashank Kumar, et al.
Published: (2023-03-01)

Synergistic effects of combined cisplatin and Clinacanthus nutans extract on triple negative breast cancer cells
by: Nur Fitriyani Afiqah Binti Abu Bakar, MSc, et al.
Published: (2023-12-01)

Molecular Investigation on a Triple Negative Breast Cancer Xenograft Model Exposed to Proton Beams
by: Francesco P. Cammarata, et al.
Published: (2020-09-01)

Diverging prognostic effects of CD155 and CD73 expressions in locally advanced triple-negative breast cancer
by: Neslihan Cabioglu, et al.
Published: (2023-07-01)

Moment of truth-adding carboplatin to neoadjuvant/adjuvant chemotherapy in triple negative breast cancer improves overall survival: An individual participant data and trial-level Meta-analysis
by: Neha Pathak, et al.
Published: (2022-08-01)

Cancer-Specific Outcomes in the Elderly with Triple-Negative Breast Cancer: A Systematic Review
by: Jenny Yoon, et al.
Published: (2021-06-01)

Systems Medicine Design for Triple-Negative Breast Cancer and Non-Triple-Negative Breast Cancer Based on Systems Identification and Carcinogenic Mechanisms
by: Shan-Ju Yeh, et al.
Published: (2021-03-01)

Benzo[<i>f</i>]indole-4,9-dione Derivatives Effectively Inhibit the Growth of Triple-Negative Breast Cancer
by: Fabiana Sélos Guerra, et al.
Published: (2021-07-01)

The Mutational Spectrum of Pre- and Post-Neoadjuvant Chemotherapy Triple-Negative Breast Cancers
by: Adriana Aguilar-Mahecha, et al.
Published: (2023-12-01)